Disseminated peritoneal leiomyomatosis (DPL) is a rare gynecologic disease involving multifocal proliferation of myomas. The pathogenesis remains unclear. Although there is no standard treatment, medical therapies have attempted to suppress estrogen levels by using gonadotrophin-releasing hormone agonist and aromatase inhibitor (AI) therapy with differing degrees of success. Surgery is also an option in symptomatic patients, and in the event of partial or no response to medical treatments. We report a case of DPL in a young woman with a previous history of myomectomy. She was treated sequentially with ulipristal acetate and AI.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187347PMC
http://dx.doi.org/10.1093/jscr/rjac166DOI Listing

Publication Analysis

Top Keywords

medical treatments
8
disseminated peritoneal
8
peritoneal leiomyomatosis
8
treatments disseminated
4
leiomyomatosis case
4
case report
4
report disseminated
4
leiomyomatosis dpl
4
dpl rare
4
rare gynecologic
4

Similar Publications

Introduction: Unmet health care needs are seen as a key indicator of equity in access to health care. With younger people, they can lead to poorer health outcomes in adulthood, and in older people they can be associated with an increased risk of mortality. The presence of a disability is considered a risk factor for unmet needs.

View Article and Find Full Text PDF

Sustained effects after a multidisciplinary lifestyle modification program for overweight and obese children.

Obes Res Clin Pract

January 2025

Department of Pediatrics, National Taiwan University Hospital, National Taiwan University Children's Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, National Taiwan University Children's Hospital, Taipei, Taiwan; Department and Graduate Institute of Medical Education and Bioethics, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address:

Background: Lifestyle modification (LM) is the mainstay in the management of obese children. This study aimed to investigate the long-term effects of a pediatric cohort participating in a hospital-based LM program.

Methods: Overweight/obese children and adolescents who visited a multidisciplinary LM program "The Health and Vitality Clinic" were included.

View Article and Find Full Text PDF

A scoping review of interventions to optimize medication adherence in hypertension comorbidity.

Res Social Adm Pharm

January 2025

Department of Pharmacy Practice and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, University of Ghana, P. O. Box LG 43, Legon, Ghana. Electronic address:

Background: Patients with hypertension and other comorbidities have difficulties adhering to their medications which have negative impacts on clinical outcomes. Although some studies have identified strategies to improve medication adherence, a thorough analysis of these interventions will provide synthesized evidence for clinical decision-making and improved health outcomes for patients with hypertension comorbidities.

Aim: To conduct a scoping review on interventions that have been utilised to improve medication adherence in patients with hypertension and other co-morbid conditions.

View Article and Find Full Text PDF

ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update.

Ann Oncol

January 2025

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Background: The availability and affordability of safe, effective cancer therapies are core requirements for effective cancer control. Global disparities exist in access, however, yielding unequal cancer outcomes. The goal of this study was to provide updated data regarding the formulary availability, out-of-pocket costs, and accessibility of cancer medicines in countries across the full spectrum of economic development areas.

View Article and Find Full Text PDF

Background: To evaluate the real-world surgical and pathological outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre national cohort of patients.

Methods: Retrospective analysis on consecutive patients treated in three tertiary referral hospitals in UK with neoadjuvant chemotherapy and immunotherapy (nivolumab) for stage II-IIIB nonsmall cell lung cancer (March 2023-May 2024). Surgical and pathological outcomes were assessed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!